EASYSIX VACCINE
Dispute with Sanofi settled, Panacea scrip soars to over 3-yr highPanacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High Court case involve...
Panacea, Sanofi settle patent litigation over hexavalent vaccinePanacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Sh...
Panacea Biotec gets $20 million loan from US government for hexavalent vaccine capacity expansionPanacea Biotec has secured a $20 million long-term loan from the US International Development Finance Corporation to expand its hexavalent ...
DFC commits USD 20 mn long-term loan to Panacea BiotecUS International Development Finance Corporation has committed a long-term loan of up to USD 20 million to Panacea Biotec. The funds will h...
Panacea Biotec files suit against Sanofi for patent infringement"The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent ...
Are companies bribing doctors to push vaccine combos?Paediatricians question these huge price increases with the addition of just one more vaccine.
Panacea Biotec says newly developed vaccine works better than its peersEasySixTM is a fully liquid ready-to-use hexavalent vaccine made using high quality antigens complying to WHO’s cGMP requirements."
Load More